Sana Biotechnology Q3 2023 GAAP net income $1.0M; cash $268.6M, pipeline data expected 2023-2024

Sana Biotechnology, Inc.

2023-Q3 EPS reported -$1.01

Q3 2023 GAAP net income $1.0M driven by $82.6M gain from fair value changes on success payment liabilities.
Cash position $268.6M; expects 2024 operating cash burn below $200M, runway into 2025.
Phase 1 ARDENT trial for SC291 (CD19-directed CAR T) enrolling; initial data expected 2023, more robust in 2024.
CTA submitted for IST of HIP-modified primary islet cells in type 1 diabetes; data expected 2023 and 2024.
IND submitted for SC291 in B-cell autoimmune diseases; SC262 IND on track for 4Q 2023; data expected 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Sana Biotechnology, Inc. reported financial results for third quarter 2023.

Period: third quarter 2023
Result: reported results

Exact text from the filing

On November 8, 2023, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Sana Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-061130

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.